Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

NCT05245838 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Shingles
Herpes Zoster
Vaccine-Preventable Diseases

Interventions

BIOLOGICAL: Z-1018
BIOLOGICAL: Z-1018
BIOLOGICAL: Z-1018
BIOLOGICAL: Z-1018
BIOLOGICAL: Shingrix

Sponsor

Dynavax Technologies Corporation